You are completely missing the point. DOC just did a deal similar to Amgen’s deal on NEO. Except that unlike Amgen, ONCS paid nothing up front and apparently no milestones either. If Amgen had done this to ADXS you would have said Amgen stole the construct. Yet now that ONCS has done it you claim it’s a bad deal. Surrrrre ....
Market Data 
Markets 
AI
